Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Liabilities: 2010-2025

Historic Total Liabilities for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $68.8 million.

  • Lineage Cell Therapeutics' Total Liabilities rose 116.49% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year increase of 116.49%. This contributed to the annual value of $36.2 million for FY2024, which is 7.15% down from last year.
  • Lineage Cell Therapeutics' Total Liabilities amounted to $68.8 million in Q3 2025, which was up 57.58% from $43.7 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Total Liabilities registered a high of $83.6 million during Q4 2021, and its lowest value of $11.2 million during Q2 2021.
  • Moreover, its 3-year median value for Total Liabilities was $39.0 million (2023), whereas its average is $41.0 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Total Liabilities surged by 552.37% in 2021, and later slumped by 38.16% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Total Liabilities (Quarterly) stood at $83.6 million in 2021, then plummeted by 38.16% to $51.7 million in 2022, then decreased by 24.61% to $39.0 million in 2023, then dropped by 7.15% to $36.2 million in 2024, then surged by 116.49% to $68.8 million in 2025.
  • Its Total Liabilities stands at $68.8 million for Q3 2025, versus $43.7 million for Q2 2025 and $34.1 million for Q1 2025.